36th Annual Rheumatology Symposium – Systems in Inflammation: From Vasculitis to Scleroderma

Friday, April 24, 2026, 7:00 AM - 5:00 PM, Courtyard by Marriott, Iowa City , IA

This activty offers exploration of current topics in vasculitis, cardio rheumatology, and systemic sclerosis. Sessions cover the diagnosis and management of both large and small vessel vasculitis, alongside emerging insights into how inflammation shapes cardiovascular disease. Afternoon discussions examine systemic sclerosis through a vascular and phenotypic lens, followed by an engaging Mini Thieves Market featuring clinical cases.

AMA PRA Category 1 Credits™ (5.75 hours), ACPE Credit (5.75 hours), ANCC Contact Hours (5.75 hours), Non-Physician Attendance (5.75 hours)

1. Distinguish between classification criteria for vasculitis and scleroderma.
2. Recommend diagnostic modalities for vasculitis and scleroderma.
3. Compare existing treatments for vasculitis and scleroderma to treatments in current clinical trials.
4. Identify traditional and non-traditional CV risk factors in autoimmune diseases to better stratify patient risk.
5. Demonstrate effective interprofessional communication for enhancing patient care

Physician $65
Allied Health Provider/Nurse $60
UI Physician* $0
UI Allied Health/Nurse* $0
Fellow/Resident/Student** 0

*Must have a HawkID to receive the UI affiliated rate.  

**Student is defined as an individual going to school full-time or part-time, not holding a current license to practice, and not needing CE credit. 

No refunds for canceled registrations after April 17, 2026.

In support of improving patient care, the University of Iowa Roy J. and Lucille A. Carver College of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Pharmacist : The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this knowledge-based activity for a maximum of 5.75 ACPE contact hours. Credit will be uploaded to the NABP CPE Monitor within 60 days after the activity completion. Pharmacists must provide their NABP ID and DOB (MMDD) to receive credit.  JA0000310-0000-26-041-L01-P

Nurse: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this activity for a maximum of 5.75 ANCC contact hours.

Other Health Care Provider: A certificate of participation will be available after successful completion of an online evaluation. It is the responsibility of the licensees to determine if this continuing education activity meets the requirements of their professional licensure board.

DISCLOSURE POLICY: University of Iowa Roy J. and Lucille A. Carver College of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships have been mitigated prior to the commencement of the activity.

You are not logged in.

Please click the button below to login or create a new account before continuing.

Mitigation of Relevant Financial Relationships

University of Iowa Roy J. and Lucille A. Carver College of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships have been mitigated prior to the commencement of the activity.